Search Bar & Filters
Found 81 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AV-380, an immunoglobulin G1 monoclonal antibody designed to bind human growth differentiation factor 15 GDF-15, a cytokine involved in cancer-induced cachexia. This phase 1B open-label dose escalation study aims to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of AV-380 in cancer patients who have cachexia and elevated GDF-15 levels. Participants have metastatic solid tumors and are actively receiving standard of care chemotherapy. Participants receive AV-380 through intravenous infusion in ascending dose cohorts alongside their standard chemotherapy treatments. The study includes a dose escalation phase where the safety and appropriate dosage of AV-380 are evaluated. This phase allows researchers to monitor the effects of increasing doses of AV-380 over a study period of up to 4 months while patients continue their usual cancer therapies. During the study, participants will undergo assessments including monitoring for adverse events, toxicity, and laboratory abnormalities from enrollment until about 60 days after the last dose. Pharmacokinetic measures such as maximum concentration Cmax, time to maximum concentration Tmax, and area under the curve AUC will also be evaluated. The total involvement includes regular evaluations to track safety, drug behavior in the body, and immune responses to AV-380.
Actively Recruiting
Researchers are studying MEN2312, a lysine acetyltransferase 6 KAT6 inhibitor, in adults with advanced breast cancer that is not curable. This first-in-human, phase 1 study evaluates MEN2312 alone and in combination with elacestrant to understand its safety and determine the best dose. Participants have specific genetic alterations in their tumors and have received prior endocrine therapy and cyclin-dependent kinase 4 and 6 inhibitor treatment. Participants will be randomly assigned to receive either MEN2312 by itself or MEN2312 combined with elacestrant, both given as oral tablets. The study follows a sequential design and aims to identify dose-limiting toxicities and recommend the phase 2 dose over several months of treatment. This includes monitoring drug levels in the body and how the body processes the medications. During the study, participants will have regular assessments to monitor side effects, tumor response, and overall health. These include evaluating the number of dose-limiting toxicities within the first 28 days and tracking response rates, progression-free survival, and overall survival for up to nine months after treatment ends. Researchers will also measure drug concentration and excretion to better understand the treatment effects and safety over time.
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
Researchers are conducting a first-in-human, open-label phase 1 study to evaluate the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and early anti-tumor effects of EPI-326. This study focuses on patients with locally advanced or metastatic non-small cell lung cancer NSCLC that has an EGFR mutation, as well as patients with head and neck squamous cell carcinoma HNSCC. The investigational drug EPI-326 is a tissue-selective bispecific antibody targeting EGFR-driven cancers. Participants will receive ascending doses of EPI-326 administered by intravenous infusion in a clinical setting. Treatment will continue until disease progression, unacceptable side effects, withdrawal of consent, or study termination. This study is conducted at multiple centers and aims to determine the recommended dose and schedule for EPI-326. During the study, participants will be monitored for safety and tolerability, with blood tests measuring drug concentrations over time. Researchers will assess tumor response and duration of response. The study duration can be up to three years, allowing for comprehensive evaluation. Participants will have regular assessments to track their health status and treatment effects throughout the study period.
Actively Recruiting
Researchers are evaluating PLN-101095 combined with pembrolizumab in adults with advanced or metastatic solid tumors that have progressed despite prior pembrolizumab treatment. This Phase 1a1b open-label study aims to assess the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and early signs of antitumor activity of this combination in patients with documented resistance to immune checkpoint inhibitors. The study includes two parts Part 1 involves consecutive dose-escalation cohorts of PLN-101095 at varying doses 250 mg to 2000 mg, administered twice or three times daily combined with pembrolizumab given intravenously every three weeks. Part 2 expands dosing cohorts to evaluate the combination and PLN-101095 monotherapy in specific tumor types, including non-small cell lung cancer, clear cell renal cell carcinoma, and tumor mutational burden-high solid tumors. Participants undergo treatment cycles with regular safety and tumor assessments, including monitoring of side effects and drug levels. Researchers will measure outcomes such as safety and tolerability from first dose through 16 weeks post-treatment, as well as antitumor activity until disease progression or death. The study spans up to several years, with ongoing evaluations to understand the treatments effects and duration of response.
Actively Recruiting
Researchers are evaluating zanidatamab combined with chemotherapy for people with early-stage HER2-positive breast cancer. This Phase 2 trial aims to determine if this combination is safe and effective compared to standard treatments. Participants have newly diagnosed Stage II or III invasive breast cancer confirmed to be HER2-positive, with specific health and organ function requirements. Participants are randomly assigned to one of three groups zanidatamab with paclitaxel, zanidatamab with docetaxel and carboplatin, or trastuzumab and pertuzumab with docetaxel and carboplatin. All drugs are given intravenously before surgery. After completing the neoadjuvant therapy, participants will have a mastectomy or breast conserving surgery as decided by their doctor. During the study, participants will have regular assessments including heart function tests, adverse event monitoring, and evaluations of tumor response up to 8 months. Additional follow-up for safety and survival outcomes extends up to nearly 4 years. Researchers will measure the number of participants achieving complete tumor response, side effects, and long-term survival, while monitoring drug levels and immune reactions.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VS-7375, alone and combined with cetuximab or panitumumab, as well as cetuximab plus mFOLFOX chemotherapy, in patients with metastatic colorectal cancer that has a KRAS G12D mutation. This phase 2 study focuses on patients who have either not received prior treatment or have progressed after previous therapies. The goal is to understand how well these treatments work and how safe they are for this specific cancer type. Participants receive one of several treatment regimens VS-7375 alone or combined with cetuximab or panitumumab for patients with second-line or later metastatic colorectal cancer, or VS-7375 combined with cetuximab and mFOLFOX chemotherapy for patients newly diagnosed or with limited prior treatment. The study involves daily oral dosing of VS-7375 and intravenous infusions of the other drugs. Treatments are assigned randomly in a 21 ratio, and participants may cross over between treatments. Throughout the study, participants attend regular visits for evaluations including tumor assessments using RECIST criteria, safety and tolerability monitoring, blood tests for drug levels and tumor markers, and quality of life questionnaires. These assessments occur over periods ranging from 6 months to 2.5 years. The study measures confirmed tumor response rates and monitors for side effects to better understand the potential of these treatments for metastatic colorectal cancer. Participation may last until study completion in late 2028.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VS-7375, given alone and combined with cetuximab, in patients with metastatic non-small cell lung cancer NSCLC that have a specific KRAS G12D mutation. This phase 2 open-label study focuses on patients who have already received prior treatments and whose cancer has progressed. The goal is to better understand how this oral KRAS G12D inhibitor works in this advanced lung cancer setting. Participants will receive VS-7375 orally in one of several dosing regimens depending on their prior treatments and disease characteristics, including groups for second or third line 2L3L therapy and those with brain metastases receiving second to fourth line 2L-4L therapy. The study uses a randomized crossover design and will assess responses to treatment over time. Different doses may be provided, and participants may be monitored for disease progression and side effects during the treatment period. Throughout the trial, participants will have regular evaluations including imaging scans to measure tumor size according to RECIST criteria, safety assessments, blood tests for pharmacokinetics and pharmacodynamics, and quality of life questionnaires. The main outcomes include confirmed tumor response rates and safety over six months, with additional measures tracked up to 2.5 years. The study will also observe time to next therapy and health-related quality of life changes, with monitoring continuing through the planned study period until 2028.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VS-7375, an oral KRAS G12D ONOFF inhibitor, alone and combined with cetuximab in patients with metastatic pancreatic ductal adenocarcinoma PDAC that has the KRAS G12D mutation. This Phase 2, open-label study aims to understand how these treatments work in this specific patient group. The trial is sponsored by Verastem, Inc. and uses a randomized, parallel design.
Actively Recruiting
Researchers are studying HMPL-A251, a drug being tested for safety, tolerability, and effectiveness in adults with unresectable, advanced, or metastatic HER2-expressing solid tumors. This first-in-human, open-label, multicenter study aims to find the best dose to use in future phases and to observe how participants respond to the treatment. The study is sponsored by Hutchmed and involves phases 1 and 2a to evaluate the drugs effects in solid tumors previously treated. Participants will receive HMPL-A251 through an intravenous infusion. The study has two parts a dose escalation phase where different dose levels are tested to find the maximum tolerated dose or recommended dose for further study, and a dose expansion phase where participants are randomized to receive one of two recommended dose levels. Treatment continues until the disease progresses, unacceptable side effects occur, or other protocol criteria are met. Throughout the study, participants will undergo evaluations including safety assessments, monitoring of side effects, and scans to measure tumor response based on RECIST criteria. Researchers will collect data on treatment-emergent adverse events, response rates, disease control, survival, and drug levels in the blood over approximately two years. Participants will be closely monitored with regular visits and assessments to track their progress and study outcomes during and after treatment.
1-10 of 81
1